Eagle Health Investments LP Decreases Stock Holdings in Illumina, Inc. $ILMN

Eagle Health Investments LP lessened its stake in Illumina, Inc. (NASDAQ:ILMN) by 6.1% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 322,261 shares of the life sciences company’s stock after selling 21,100 shares during the quarter. Illumina comprises approximately 8.0% of Eagle Health Investments LP’s investment portfolio, making the stock its 5th biggest holding. Eagle Health Investments LP’s holdings in Illumina were worth $30,605,000 as of its most recent SEC filing.

A number of other large investors also recently modified their holdings of ILMN. Wealthcare Advisory Partners LLC grew its stake in shares of Illumina by 2.8% during the third quarter. Wealthcare Advisory Partners LLC now owns 9,164 shares of the life sciences company’s stock valued at $870,000 after purchasing an additional 248 shares during the last quarter. Rothschild Investment LLC lifted its holdings in Illumina by 514.9% during the 3rd quarter. Rothschild Investment LLC now owns 2,675 shares of the life sciences company’s stock worth $254,000 after buying an additional 2,240 shares in the last quarter. Skandinaviska Enskilda Banken AB publ boosted its position in Illumina by 32.6% in the 3rd quarter. Skandinaviska Enskilda Banken AB publ now owns 74,195 shares of the life sciences company’s stock valued at $7,046,000 after buying an additional 18,253 shares during the last quarter. JPMorgan Chase & Co. increased its stake in shares of Illumina by 17.5% in the 3rd quarter. JPMorgan Chase & Co. now owns 832,690 shares of the life sciences company’s stock valued at $79,081,000 after buying an additional 124,246 shares during the period. Finally, State of New Jersey Common Pension Fund D increased its stake in shares of Illumina by 4.3% in the 3rd quarter. State of New Jersey Common Pension Fund D now owns 57,056 shares of the life sciences company’s stock valued at $5,419,000 after buying an additional 2,350 shares during the period. 89.42% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several equities analysts recently issued reports on the company. Stifel Nicolaus raised their price target on Illumina from $135.00 to $155.00 and gave the company a “buy” rating in a report on Tuesday, January 20th. Wall Street Zen upgraded shares of Illumina from a “buy” rating to a “strong-buy” rating in a research report on Saturday. Zacks Research cut shares of Illumina from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, December 31st. Robert W. Baird set a $137.00 price target on shares of Illumina in a research note on Friday, February 6th. Finally, UBS Group reaffirmed a “neutral” rating and issued a $135.00 price objective on shares of Illumina in a research note on Friday, February 6th. Six analysts have rated the stock with a Buy rating, eleven have assigned a Hold rating and two have assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus price target of $127.94.

Insider Transactions at Illumina

In other news, insider Scott M. Davies sold 323 shares of the stock in a transaction on Friday, December 12th. The shares were sold at an average price of $136.09, for a total transaction of $43,957.07. Following the completion of the sale, the insider owned 17,887 shares of the company’s stock, valued at $2,434,241.83. This represents a 1.77% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders own 0.17% of the company’s stock.

Illumina Price Performance

ILMN opened at $116.51 on Wednesday. The company has a quick ratio of 1.72, a current ratio of 2.08 and a debt-to-equity ratio of 0.55. Illumina, Inc. has a 12 month low of $68.70 and a 12 month high of $155.53. The company has a fifty day simple moving average of $136.77 and a 200 day simple moving average of $116.89. The stock has a market cap of $17.81 billion, a P/E ratio of 21.38, a P/E/G ratio of 2.23 and a beta of 1.45.

Illumina (NASDAQ:ILMN) last posted its earnings results on Thursday, February 5th. The life sciences company reported $1.35 earnings per share for the quarter, topping the consensus estimate of $1.26 by $0.09. Illumina had a return on equity of 31.04% and a net margin of 19.57%.The firm had revenue of $1.16 billion for the quarter, compared to analyst estimates of $1.10 billion. During the same period in the previous year, the company posted $0.95 earnings per share. The company’s revenue for the quarter was up 5.0% on a year-over-year basis. Illumina has set its FY 2026 guidance at 5.050-5.200 EPS. On average, research analysts expect that Illumina, Inc. will post 4.51 EPS for the current year.

About Illumina

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.